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Abstract
Background: Oligohydramnios sequence can be caused by renal tubular dysgenesis (RTD), a rare condition
resulting in pulmonary and renal morbidity. Besides typical features of Potter-sequence, the infants present with
severe arterial hypotension and anuria as main symptoms. Establishing an adequate arterial blood pressure and
sufficient renal perfusion is crucial for the survival of these infants.
Case presentation: We describe a male preterm infant of 34 + 0weeks of gestation. Prenatally oligohydramnios of
unknown cause was detected. After uneventful delivery and good adaptation the infant developed respiratory distress
due to a spontaneous right-sided pneumothorax and required thoracocentesis and placement of a chest tube; he
showed no major respiratory concerns thereafter and needed only minimal ventilatory support. Echocardiography
revealed no abnormalities, especially no pulmonary hypertension. However, he suffered from severe arterial hypotension
and anuria refractory to catecholamine therapy (dobutamine, epinephrine and noradrenaline). After 36 h of life,
vasopressin therapy was initiated resulting in an almost immediate stabilization of arterial blood pressure and subsequent
onset of diuresis. Therapy with vasopressin was necessary for three weeks to maintain adequate arterial blood pressure
levels and diuresis. Sepsis and adrenal insufficiency were ruled out as inflammation markers, microbiological tests and
cortisol level were normal. At two weeks of age, our patient developed electrolyte disturbances which were successfully
treated with fludrocortisone. He did not need renal replacement therapy. Genetic analyses revealed a novel compound
hyterozygous mutation of RTD. Now 17months of age, the patient is in clinically stable condition with treatment of
fludrocortisone and sodium bicarbonate. He suffers from stage 2 chronic kidney disease; blood pressure, motor and
cognitive development are normal.
Conclusions: RTD is a rare cause of oligohydramnios sequence. Next to pulmonary hypoplasia, severe arterial
hypotension is responsible for poor survival. We present the only second surviving infant with RTD, who did not require
renal replacement therapy during the neonatal period. It can be speculated whether the use of vasopressin prevents
renal replacement therapy as vasopressin increases urinary output by improving renal blood flow.
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Background
Oligohydramnios sequence remains a challenge for the
neonatologist as most affected neonates present with con-
siderable pulmonary morbidity and arterial hypotension.
Renal tubular dysgenesis (RTD) is a rare condition result-
ing in oligohydramnios sequence with refractory arterial
hypotension significantly complicating the course of treat-
ment. Diagnosis of RTD can be challenging due to the
lack of concrete findings on renal ultrasound. Managing
arterial hypotension and concomitant anuria is crucial for
survival. We report a preterm infant with refractory
hypotension and anuria which was successfully treated
with vasopressin.
Case presentation
Perinatal and neonatal outcome
The male infant was born to a 23 year-old primi-gravida
mother. Pregnancy was uneventful, fetal urinary tract
appeared normal on ultrasound, the mother’s medical
history was negative for any medication as was family
history for renal or cardiovascular disease. While amni-
otic fluid volume seemed normal on routine ultrasound
examinations, anhydramnios of unknown origin was
observed at 32 weeks of gestation. No signs of tear or
leak in the amniotic membrane were detected. Anhy-
dramnios and pathological umbilical blood flow led to
Caesarean section at 34 + 0 weeks of gestation. Birth-
weight was 2515 g (66th percentile), head circumference
31 cm (24th percentile), APGAR scores 9 at 5′ and 10 at
10 min, umbilical cord artery pH 7.35. The anterior fon-
tanelle was wide and the infant showed features of
Potter-sequence with contractures of wrist and ankle
joints as well as epicanthus. He also presented with
distinct general edema.
After good postnatal adaptation, the infant needed
mechanical ventilation due to respiratory distress caused
by a spontaneous right-sided pneumothorax at the age
of 1 h. He quickly stabilized after nasotracheal intubation
and placement of a chest tube. Neither signs of pulmonary
hypoplasia nor pulmonary hypertension were evident
from chest x-ray or echocardiography (see Fig. 1a and b).
Pre- and postductal oxygen saturation monitoring did not
show any significant difference, ventilatory support was
minimal (SIMV-mode, PIP 13mbar, FiO2 0,25) and the
patient had no signs of surfactant deficiency.
During the first day of life, he developed severe arterial
hypotension (mean arterial blood pressure around 30
mmHg, below 10th percentile [1]) and consecutive renal
failure and anuria (no urinary output for 36 h, serum
creatinine 1,98 mg/dl, blood urea nitrogen (BUN) 120
mg/dl) which poorly responded to fluid boluses,
catecholamine therapy (dobutamine, noradrenaline and
epinephrine), furosemide and hydrocortisone therapy.
Sepsis, cystic kidney disease and connatal nephrotic syn-
drome were ruled out. The cortisol level was normal.
Echocardiography revealed good biventricular function
without signs of pulmonary hypertension.
After 36 h, vasopressin therapy was initiated with
excellent response at doses of 0,001 IE/kg/min; blood
pressure stabilized with consecutive onset of diuresis
almost immediately after starting of vasopressin (see
Fig. 2). Initially elevated creatinine and blood urea nitro-
gen normalized with the onset of diuresis. Weaning of
vasopressin, however, was difficult due to rapid deterior-
ation of blood pressure and urinary output and could
not be discontinued for the next three weeks. Oligohy-
dramnios, refractory arterial hypotension, renal failure
with normal renal ultrasound was highly suggestive of
renal tubular dysgenesis. On the fourth day of life, the
patient suffered from a spontaneous gastric perforation,
which was surgically treated without complications (see
Fig. 3). On the 21st day of life, hyperkalemia needed to
be treated with repetitive doses of furosemide. As renal
tubular dysgenesis was suspected, endocrinological
Fig. 1 Chest X-rays on the first day of life. a spontaneous right-sided pneumothorax b) after intubation and chest tube insertion
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assessment was performed on day 12. It revealed an exces-
sively high active renin concentration > 330 ng/l (normal
6.3 to 149 ng/l), a low concentration of ACE < 8U/l (nor-
mal 8.3 to 21.4 U/l) and hypoaldosteronism (aldosterone
< 37 ng/l, normal 73–425 ng/l). As this is a common find-
ing in RTD, we established a fludrocortisone therapy
resulting in stable electrolytes and bicarbonate. The infant
required a gastric tube due to poor feeding until the 6th
week of life. He was discharged at the age of 7 weeks.
Mutational analysis of the ACE gene showed a novel
compound hyterozygous mutation. C.5303 + 1G > A has
been described before and impairs splicing of pre-mRNA
of ACE [2]. The other mutation was c.1487G >A and has
not been reported before in RTD. Therefore, we present a
patient with a novel compound hyterozygous constellation
of RTD.
Long term outcome
The patient is now 17months of age and has been
re-admitted several times for dehydration due to poor feed-
ing in times of respiratory infection. Whenever fludrocorti-
sone therapy was discontinued due to non-compliance, the
patient developed hyperkalemia and rise of creatine levels.
Currently he is suffering from stage 2 chronic renal disease
with a GFR of 60ml/min/1,73m2 (normal > 90ml/min/
1,73m2). Renal ultrasound shows increased echogenicity
but no enlargement of the kidneys. With reestablished
fludrocortisone therapy and sodium bicarbonate substitu-
tion electrolytes and blood urea nitrogen are normal, serum
creatinine and cystatine C only slightly elevated (Creatinine
0,45mg/dl, cystatine C 1,43mg/l). Blood pressure is on the
50th percentile. Cognitive and psychomotor development
are age-appropriate.
Discussion
RTD is a rare disorder, characterized by prematurity,
oligo- or anhydramnios, severe arterial hypotension and
neonatal renal failure. It is a hyterozygous inherited
autosomal-recessive disease with over 50 reported muta-
tions [2]. It affects angiotensinogen, angiotensinogen
receptor 1, renin or angiotensin converting enzyme
genes in the Renin angiotensin system (RAAS) without a
predictive genotype-phenotype correlation so far. Similar
clinical findings have been observed in children exposed
to RAAS blockage during pregnancy [3], highlighting
the importance of RAAS for kidney development. So far,
Fig. 2 Blood pressure and diuresis during the first three days of life. This figure displays changes in blood pressure (systolic, diastolic and mean
arterial pressure) as well as rate of diuresis in relation to the medication applied. See the immediate onset of diuresis after the initiation of
vasopressin therapy
Fig. 3 Chest X-ray depicting free abdominal air due to
gastric perforation
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about 150 cases of RTD have been published [2], how-
ever, only about 10 long-term survivors have been
reported [2, 4]; in most cases RTD is fatal either in utero
or shortly after birth [5]. Differentiated proximal tubules
are significantly reduced or even absent [5] on histo-
logical examinations of the patients’ kidneys. Prenatal
signs of RTD are oligo- or anhydramnios and lack of
concrete findings in prenatal urinary tract ultrasound.
After birth, hallmark signs are a varying degree of Potter
sequence with facial abnormalities and pulmonary
hypoplasia, hypocalvaria and contractures of joints
[2]. Patients present with severe, therapy refractory
arterial hypotension, anuria and usually need respira-
tory support [5].
Hypotension and anuria amongst reported survivors
were refractory to the usual treatment of fluid boluses,
furosemide, catecholamine therapy and hydrocortisone
treatment. Nearly all patients required peritoneal dialysis
for the first days or weeks of life until diuresis was estab-
lished. In two reported cases the continuous infusion of
Fresh Frozen Plasma helped to increase blood pressure
but peritoneal dialysis was still necessary [6, 7]. Only
one child is reported so far that did not need peritoneal
dialysis. Richer et al. report a preterm infant (26 + 5 ges-
tational age) developing adequate blood pressure and di-
uresis when started on continuous vasopressin infusion
on day 8 of life [8]. Our patient is only the second one
described without renal replacement therapy in the neo-
natal period and also the second one having received
vasopressin.
The application of intravenous vasopressin increases
arterial blood pressure by a direct vasoconstrictive effect
via V1 receptors and a local inhibition of nitric oxide
production. At the same time, renal blood flow is
enhanced possibly through selective efferent arteriolar
constriction and nitric oxide mediated afferent arteriolar
vasodilatation [9]. Some studies have found vasopressin
helpful in catecholamine refractory arterial hypotension
in septic and cardiac shock although its role is not yet
clear [10]. In these studies, vasopressin significantly
raised mean arterial blood pressure and urinary output
[9, 11].
In all reported survivors of RTD, blood pressure and
diuresis normalized, hypoaldosteronism though, per-
sisted in most cases, rendering a fludrocortisone therapy
necessary [2, 4, 6–8].
Our patient suffered from spontaneous gastric perfor-
ation. The mechanism is unclear, a hypoperfusion of the
intestines and some intraluminal pressure for example
due to the gastric tube may be a likely explanation. Few
reports exist on gastric perforation through nasogastric
tubes in preterm infants as most perforations are seen in
the esophagus [12]. The patient reported by Kim et al.
developed an ileac perforation in the neonatal period [4]
which may be related to arterial hypotension in RTD,
the patient reported by Richer et al. suffered from necro-
tizing enterocolitis. Whether this is related to RTD or
extreme prematurity remains uncertain [8]. Since the
number of survivors reported is small, it is difficult to
assess whether a certain percentage of these patients
suffers from intestinal perforations; however, due to
hypoperfusion of the intestines a causative relation
seems possible. Whether intestinal hypoperfusion is the
result of underlying disease or impaired microcirculation
due to the use of vasopressors remains unclear. Also, the
administration of hydrocortisone has been associated
with spontaneous intestinal perforations in the past [13].
So far, these have not been described in secondary RTD
caused by exposure to RAAS blockers during pregnancy
[3]. In patients who developed intestinal perforations,
peritoneal dialysis is not an option; all reported patients
were born preterm and of very low birthweight making
also hemodialysis impossible.
As the patient described by Kim et al. [4], the use of
vasopressin may have prevented renal replacement ther-
apy in our patient by establishing sufficient renal perfu-
sion and consecutively urinary output.
In the few survivors reported, chronic or end-stage renal
disease is present [2], in one case renal transplantation at
the age of 4 was performed [14], another patient needed
peritoneal dialysis [7]. However, as stated by the authors,
all patients show normal cognitive development.
Conclusions
RTD is a rare, severe, often fatal disease and should be
considered in infants with oligohydramnios sequence
without sonographic renal abnormalities suffering from
severe arterial hypotension. Respiratory failure and se-
vere hypotension with anuria are the major challenges in
the first days of life. Early treatment with vasopressin
prevented peritoneal dialysis in the two cases known and
may be the vasopressor of choice in this disease. It
seems to be the only agent for establishing sufficient
renal perfusion. Whether vasopressin is the key to treat-
ing arterial hypotension and preventing renal replace-
ment therapy in patients with RTD needs to be further
studied. If RTD is suspected in an infant and severe
arterial hypotension persists despite high doses of
catecholamines, the use of vasopressin may be consid-
ered a therapeutic option.
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